Oticon: Covid-19 led to debates about product launches

The unpredictable world situation in the spring of 2020 meant that the timing of product launches was frequently discussed at Demant-owned Oticon, located in Denmark.

Photo: Oticon/PR

The corona pandemic brought with it large-scale lockdowns all over the world last year, alongside a near-complete meltdown of the hearing aid market, particularly in March, April and May.

While the markets stood still, the opposite was true of development departments in the hearing aid industry, as several new product platforms were launched over the summer.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs